Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| muscarinic receptors agonists/antagonists | 676 | 7020-55-5 |
None
None
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 | 20 | |||
| kinase-selectivity-class | AXL,GRK2,PDK4 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | ROCHE |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Apraxia | 62.01 | 30.18 | 12 | 1004 | 2250 | 90625181 |
| Disorientation | 54.68 | 30.18 | 20 | 996 | 44094 | 90583337 |
| Perseveration | 54.64 | 30.18 | 8 | 1008 | 277 | 90627154 |
| Hyperreflexia | 44.06 | 30.18 | 11 | 1005 | 6646 | 90620785 |
| Cognitive disorder | 39.47 | 30.18 | 18 | 998 | 69389 | 90558042 |
| Myoclonus | 36.55 | 30.18 | 12 | 1004 | 19156 | 90608275 |
| Cholecystitis chronic | 30.78 | 30.18 | 9 | 1007 | 9817 | 90617614 |
| Dementia | 30.21 | 30.18 | 11 | 1005 | 23850 | 90603581 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Apraxia | 61.22 | 31.02 | 12 | 835 | 3528 | 110584924 |
| Perseveration | 54.46 | 31.02 | 8 | 839 | 419 | 110588033 |
| Hyperreflexia | 44.36 | 31.02 | 11 | 836 | 9474 | 110578978 |
| Disorientation | 42.30 | 31.02 | 17 | 830 | 70654 | 110517798 |
| Cognitive disorder | 38.80 | 31.02 | 17 | 830 | 87494 | 110500958 |
| Myoclonus | 34.66 | 31.02 | 12 | 835 | 32986 | 110555466 |
| Cholecystitis chronic | 34.48 | 31.02 | 9 | 838 | 9491 | 110578961 |
| Dementia | 31.27 | 31.02 | 11 | 836 | 31662 | 110556790 |
None
| Source | Code | Description |
|---|---|---|
| ATC | A03CA02 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Synthetic anticholinergic agents in combination with psycholeptics |
| FDA PE | N0000008779 | Decreased Parasympathetic Acetylcholine Activity |
| FDA PE | N0000009022 | Digestive/GI System Activity Alteration |
| FDA PE | N0000009048 | GI Motility Alteration |
| FDA MoA | N0000175370 | Cholinergic Antagonists |
| FDA EPC | N0000175574 | Anticholinergic |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:50370 | parasympatholytic |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| MeSH PA | D010276 | Parasympatholytics |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Irritable bowel syndrome | indication | 10743008 | DOID:9778 |
| Enterocolitis | indication | 43752006 | |
| Brain damage | contraindication | 2470005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Hyperactive behavior | contraindication | 44548000 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Peptic reflux disease | contraindication | 57643001 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Psychotic disorder | contraindication | 69322001 | |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Hypoalbuminemia | contraindication | 119247004 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Myocardial dysfunction | contraindication | 233928007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Drowsy | contraindication | 271782001 | |
| Pregnancy, function | contraindication | 289908002 | |
| Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Porphyria | contraindication | 418470004 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.67 | acidic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | CHEMBL | CHEMBL | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.60 | IUPHAR | CHEMBL |
| ID | Source |
|---|---|
| 4019682 | VUID |
| N0000179084 | NUI |
| D00716 | KEGG_DRUG |
| 3485-62-9 | SECONDARY_CAS_RN |
| 21232 | RXNORM |
| C0055877 | UMLSCUI |
| CHEBI:3743 | CHEBI |
| CHEMBL620 | ChEMBL_ID |
| CHEMBL1200950 | ChEMBL_ID |
| DB00771 | DRUGBANK_ID |
| C054940 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2784 | PUBCHEM_CID |
| 366 | IUPHAR_LIGAND_ID |
| BO76JF850N | UNII |
| 3953 | MMSL |
| 4465 | MMSL |
| d00991 | MMSL |
| 001747 | NDDF |
| 004702 | NDDF |
| 387323005 | SNOMEDCT_US |
| 57853003 | SNOMEDCT_US |
| 87283008 | SNOMEDCT_US |
| 463 | INN_ID |
| 4018831 | VANDF |
| 4019682 | VANDF |
| BO76JF850N | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Librax | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0187-4100 | CAPSULE | 2.50 mg | ORAL | NDA | 16 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0276-0500 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10135-622 | CAPSULE | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 17 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 11534-197 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42571-381 | CAPSULE | 2.50 mg | ORAL | ANDA | 21 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42582-300 | CAPSULE | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42582-301 | CAPSULE | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 18 sections |
| Chlordiazepoxide hydrochloride and clidinium bromide | Human Prescription Drug Label | 2 | 46708-744 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| Chlordiazepoxide Hydrochloride/Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-0131 | CAPSULE | 2.50 mg | ORAL | Unapproved drug other | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1528 | CAPSULE | 2.50 mg | ORAL | NDA authorized generic | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | Human Prescription Drug Label | 2 | 59651-524 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| chlordiazepoxide hydrochloride and clidinium bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60219-1677 | CAPSULE | 2.50 mg | ORAL | ANDA | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60687-639 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 62135-696 | CAPSULE | 2.50 mg | ORAL | ANDA | 14 sections |
| Chlordiazepoxide hydrochloride and clidinium bromide | Human Prescription Drug Label | 2 | 62332-744 | CAPSULE | 2.50 mg | ORAL | ANDA | 24 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-2373 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-8859 | CAPSULE | 2.50 mg | ORAL | ANDA | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | Human Prescription Drug Label | 2 | 67877-731 | CAPSULE | 2.50 mg | ORAL | ANDA | 23 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68151-2500 | CAPSULE | 2.50 mg | ORAL | NDA authorized generic | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 69189-0489 | CAPSULE | 2.50 mg | ORAL | NDA authorized generic | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70700-185 | CAPSULE | 2.50 1 | ORAL | ANDA | 18 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71186-006 | CAPSULE, GELATIN COATED | 2.50 mg | ORAL | UNAPPROVED DRUG OTHER | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71335-2966 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 71335-9764 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72162-1237 | CAPSULE | 2.50 mg | ORAL | ANDA | 19 sections |
| CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72162-2436 | CAPSULE | 2.50 mg | ORAL | ANDA | 21 sections |
| CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72162-2436 | CAPSULE | 2.50 mg | ORAL | ANDA | 21 sections |
| Chlordiazepoxide Hydrochloride and Clidinium Bromide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 75826-134 | CAPSULE | 2.50 mg | ORAL | ANDA | 20 sections |